<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Overview of management of hypertriglyceridemia</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Overview of management of hypertriglyceridemia</h1>
<div class="graphic"><div class="figure"><div class="ttl">Overview of management of hypertriglyceridemia</div><div class="cntnt"><img src="data:png;base64,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"/></div><div class="graphic_footnotes"><p>ABI: ankle-brachial index; ASCVD: atherosclerotic cardiovascular disease; HDL-C: high-density lipoprotein cholesterol; hs-CRP: high-sensitivity C-reactive protein; IPE: icosapent ethyl; LDL-C: low-density lipoprotein cholesterol; TG: fasting serum (or plasma) triglyceride level.</p>
<p>* Addressing modifiable causes includes avoiding medications that cause hypertriglyceridemia and achieving excellent glycemic control for patients with diabetes mellitus. Refer to UpToDate content on causes of hypertriglyceridemia.</p>
<p>¶ Nonpharmacologic measures include regular aerobic exercise, management of ASCVD risk factors including hypertension, and weight loss as indicated. Specific diet and alcohol recommendations vary depending upon the severity of hypertriglyceridemia. For moderate hypertriglyceridemia, targets include &lt;6% calories of added sugar, ≤30 to 35% calories of total dietary fat, and ≤2 drinks per day for males and ≤1 drink per day for females. For moderate to severe hypertriglyceridemia, targets include &lt;5% calories of added sugar, ≤20 to 25% calories of total dietary fat, and alcohol abstinence. Refer to § for targets for severe hypertriglyceridemia.</p>
<p>Δ Refer to UpToDate content on the approach to ASCVD risk assessment and on LDL-C management for primary and secondary prevention of ASCVD.</p>
<p>◊ "High ASCVD risk" is defined here according to the criteria in the REDUCE-IT trial: established ASCVD <strong>or</strong> diabetes mellitus plus two of the following ASCVD risk factors: age ≥50 years, cigarette smoking, hypertension, HDL-C ≤40 mg/dL for males or ≤50 mg/dL for females, hs-CRP &gt;3 mg/L (0.3 mg/dL), creatinine clearance &lt;60 mL/min, retinopathy, micro- or macroalbuminuria, and ABI &lt;0.9.</p>
<p>§ In the setting of severe hypertriglycedemia, it is crucial to eliminate added sugars, restrict fat to ≤10 to 15% (preferably &lt;5%) of total calories, and abstain from alcohol.</p>
<p>¥ For outpatients with severe hypertriglyceridemia, drug therapy for TG lowering (beyond therapy for LDL-C) is generally deferred. Given the rapid rate of TG lowering achievable with stringent dietary fat restriction, with close monitoring it may be possible to initiate drug therapy for hypertriglyceridemia within days. However, for inpatients with severe hypertriglyceridemia and pancreatitis, immediate treatment with a fibrate is a component of therapy.</p>
<p>‡ The choice of marine omega-3 fatty acid varies depending upon the level of ASCVD risk (as defined above). For patients with high ASCVD risk, we prefer prescription-strength IPE. In patients without high ASCVD risk, any prescription high-dose marine omega-3 fatty acid can be used. Choices include omega-3 fatty acid ethyl esters (EPA+DHA) in generic or brand form or IPE (ethyl ester of EPA). Refer to UpToDate content on administration and side effects.</p>
† When choosing fibrate therapy, we generally prefer fenofibrate to gemfibrozil since it has fewer drug interactions, is generally better tolerated, and patient compliance is better due to its once-daily dosage. Refer to UpToDate content on administration and side effects.</div><div id="graphicVersion">Graphic 133141 Version 4.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
